Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 67,036

Document Document Title
WO/2020/243415A2
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2020/243496A1
Disclosed are methods of treating a non-infectious ocular immunoinflammatory disorder in a subject. Methods of reducing a symptom, e.g., ocular redness, of a non-infectious ocular immunoinflammatory disorder in a subject, and pharmaceuti...  
WO/2020/237392A1
The present application provides methods and compositions for treatment of B cell related cancers by inhibition of PKN1. The method for treating a B cell related cancer, such as Chronic Lymphocytic Leukemia (CLL) comprises administering ...  
WO/2020/242960A1
The present disclosure provides compounds, for example, a compound of Formula (I), that modulate a protein function and/ or restore protein homeostasis. The disclosure provides a method of modulating a protein-mediated disease, disorder,...  
WO/2020/239856A1
Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.  
WO/2020/239951A1
The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositio...  
WO/2020/241614A1
Compounds represented by formula (I) or formula (II). (In formulas (I) and (II), A represents an oxygen atom or a sulfur atom, X1 represents a halogeno group or the like, m represents the number of X1s and is an integer from 0 to 5, Z re...  
WO/2020/238094A1
Disclosed are a blue green-to-orange red light thermally activated delayed fluorescent material, a preparation method therefor and the use thereof. Through molecular design, a series of thermally activated delayed fluorescent materials h...  
WO/2020/243754A1
Provided herein is a method of forming a beta-lactone from a carboxylic acid having a beta-carbon with a hydrogen atom disposed thereon. The method comprises contacting a carboxylic acid of formula (1) as described herein with an effecti...  
WO/2020/239999A1
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventin...  
WO/2020/240490A1
The present invention relates to physically and chemically stable salts of the selective histamine preceptor antagonist compound of l-[4-(4-{3-[(2R)-2-methyl-pyrrolidin-l-yl]-propoxy}-phenoxy) - piperidin-l-yl]-ethanone of formula (1) an...  
WO/2020/239853A1
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.  
WO/2020/238802A1
A crystal form and a salt form of a uracil compound acting as a c-MET/AXL inhibitor and a preparation method therefor, specifically relating to the crystal form and the salt form of the compound shown in formula (I), and also comprising ...  
WO/2020/233512A1
An aromatic amine androgen receptor (AR) and BET targeting protein degradation chimera compound and use. Specifically provided is a compound represented by formula I. Experimental results show that the compound can target and degrade bot...  
WO/2020/233583A1
The present invention relates to an isoquinolinone compound, which acts as an inhibitor of semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1), and the use thereof, and further relates to a pharmaceutical co...  
WO/2020/236692A1
The present disclosure is directed to pyridinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment of infection ...  
WO/2020/236586A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2020/236084A1
The present invention relates to a compound comprising a hydrophobic moiety, a linker and N-containing moiety. The present invention also relates to the method of synthesizing the compound and the use of the compound as an antibiotic or ...  
WO/2020/234479A1
The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination pr...  
WO/2020/233641A1
The present invention belongs to the field of medical technology and specifically disclosed is a compound represented by formula (I'), or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and each symbol there...  
WO/2020/233694A1
Disclosed are a crystal form (I) of a pyrimidine sulfonamide compound and a preparation method therefor. The present invention relates to an application thereof in the preparation of a medicament for treating diseases related to ETA rece...  
WO/2020/234333A1
The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositio...  
WO/2020/234715A1
The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): (I), wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention furth...  
WO/2020/234103A1
The present invention relates to compounds of formula (1) in which A, U and R1 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therap...  
WO/2020/234817A1
The present invention relates to novel crystalline polymorphic forms of apalutamide. The present invention also relates to processes for preparation of amorphous form of apalutamide and pharmaceutical composition containing the same.  
WO/2020/236654A1
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amena...  
WO/2020/233592A1
Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compoun...  
WO/2020/235591A1
The purpose of the present invention is to provide a novel variable resistance device, the resistance state of which is variable. Consequently, one of typical variable resistance devices according to the present invention is provided w...  
WO/2020/232056A1
In certain embodiments allosteric inhibitors of BACE are provided. Illustrative inhibitors include but are not limited to various metformin analogs.  
WO/2020/232330A1
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.  
WO/2020/228637A1
Disclosed is a compound of formula I or a pharmaceutically acceptable salt, active metabolite, tautomer, stereoisomer, or prodrug thereof as BTK (Bruton's Tyrosine Kinase) inhibitors, which is useful for the treatment of autoimmune disea...  
WO/2020/232119A1
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.  
WO/2020/230800A1
The present application discloses a method and a compound useful in the preparation of a compound represented by formula (XI). Furthermore, the present application discloses a compound that is represented by formula (XI) and that has few...  
WO/2020/230134A1
The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral...  
WO/2020/229595A1
The present invention relates to compounds of formula (I) and compositions containing said compounds acting as PARP (Poly (ADP- ribose) polymerase) inhibitors. Moreover, the present invention provides processes for the preparation of the...  
WO/2020/230100A1
The present invention provides a novel chemical process for the synthesis of the compound N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrroli din-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide.  
WO/2020/198567A8
The present disclosure provides novel compounds, compositions comprising the compounds and methods of use thereof.  
WO/2020/229968A1
The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.  
WO/2020/228729A1
The present invention relates to a crystal form of a compound of formula (I), which acts as a PI3Kα inhibitor, and a preparation method therefor, and the use thereof in the preparation of a medicine for treating solid tumors.  
WO/2020/228649A1
Disclosed are a substituted phenylpropenylpyridine derivative, a preparation method therefor and the use thereof as a PD-1/PD-L1 inhibitor. In particular, disclosed are a compound of formula (I) or a pharmaceutically acceptable salt, ste...  
WO/2020/231766A1
The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions i...  
WO/2020/232115A1
Bifunctional nutlin-lenalidomide derivatives ((4,5-dihydro-lH- imidazole-l-carbonyl) piperazin-l-yl-[linker]-l-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives) of the formula (I),as MDM2 (murine double minute 2) degraders and MDM2-...  
WO/2020/230136A1
The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral...  
WO/2020/228436A1
The present invention relates to aromatic ring or heteroaromatic ring derivatives, a preparation method therefor and applications thereof in medicine. Specifically, the present invention relates to aromatic ring or heteroaromatic ring de...  
WO/2020/230099A1
The present invention describes specific crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrroli din-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide. The present invention further relates to methods for preparin...  
WO/2020/231977A1
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the presen...  
WO/2020/224607A1
The present application provides a compound represented by formula (I), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof; and a use thereof in preparing drugs used to treat EZH2-mediated...  
WO/2020/227549A1
Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IlIa, lIIb, IlIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is ...  
WO/2020/224568A1
Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.  
WO/2020/227325A1
Disclosed are Hematopoietic Progenitor Kinase 1 (HPK1) degradation / disruption compounds including a HPK1 ligand, a degradation / disruption tag and a linker, and methods for use of such compounds in the treatment of HPK1-mediated disea...  

Matches 451 - 500 out of 67,036